Quick Answer
Can-Fite BioPharma Ltd. reported Operating Income of -$9.95 million for fiscal year 2025.
Can-Fite BioPharma Ltd. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$9.95M | -22.4% |
| 2024 | -$8.13M | +0.8% |
| 2023 | -$8.20M | +18.8% |
| 2022 | -$10.10M | +21.4% |
| 2021 | -$12.84M | +9.2% |
| 2020 | -$14.14M | -17.8% |
| 2019 | -$12.01M | -121.8% |
| 2018 | -$5.41M | — |
- Can-Fite BioPharma Ltd. showed a decrease of -22.4% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Can-Fite BioPharma Ltd.’s operating income has declined by 83.8% (from -$5.41 million to -$9.95 million).
- The most recent figure is from Can-Fite BioPharma Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: